⚙
AI-generated deep summary
by claude@2026-07, 2026-07-06
· read from full text
ⓘ
This preprint describes a pediatric case of severe, refractory autoimmune hemolytic anemia (AIHA) that did not respond adequately to conventional therapies used in childhood, including steroids, intravenous immunoglobulin, rituximab, and other immunosuppressive/chemotherapeutic approaches. After initiating bortezomib, the patient showed a dramatic recovery beginning from the first doses, with no reported adverse effects in the case. The main caveat is that the evidence comes from a single case report and is therefore limited in generalizability. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
The treatment of refractory autoimmune hemolytic anemia (AIHA) in childhood remains a significant challenge in hematology practice. Steroids, intravenous immunoglobulin (IVIG), rituximab, various immunosuppressants, and chemotherapeutic agents are commonly used. In highly refractory cases, hematopoietic stem cell transplantation may even be considered. Here, we describe a pediatric AIHA case that was highly refractory to conventional therapies but responded dramatically to bortezomib without any adverse effects. The patient showed a remarkable recovery starting from the first doses of the drug. Bortezomib may be considered as an alternative treatment option in such cases.
Full text
6,299 characters
· extracted from
preprint-html
· click to expand
SEVERE/REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA IN A CHILD SUCCESSFULLY TREATED WITH BORTEZOMIB | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 6 February 2025 V1 Latest version Share on SEVERE/REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA IN A CHILD SUCCESSFULLY TREATED WITH BORTEZOMIB Authors : Fatih DEMİRCİOĞLU 0000-0001-9582-8270 [email protected] , Zekai Avci , İbrahim AKALIN , Oğuzhan BABACAN , İlknur SUNAR , Ayşe Sena DEMİRCİOĞLU , and Betul Tavil Authors Info & Affiliations https://doi.org/10.22541/au.173883445.53583025/v1 254 views 113 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract The treatment of refractory autoimmune hemolytic anemia (AIHA) in childhood remains a significant challenge in hematology practice. Steroids, intravenous immunoglobulin (IVIG), rituximab, various immunosuppressants, and chemotherapeutic agents are commonly used. In highly refractory cases, hematopoietic stem cell transplantation may even be considered. Here, we describe a pediatric AIHA case that was highly refractory to conventional therapies but responded dramatically to bortezomib without any adverse effects. The patient showed a remarkable recovery starting from the first doses of the drug. Bortezomib may be considered as an alternative treatment option in such cases. Supplementary Material File (case report.doc) Download 85.50 KB File (table-1.docx) Download 20.46 KB Information & Authors Information Version history V1 Version 1 06 February 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Keywords anemia hemolytic anemia immune cytopenias Authors Affiliations Fatih DEMİRCİOĞLU 0000-0001-9582-8270 [email protected] Dokuz Eylul Universitesi View all articles by this author Zekai Avci Istanbul Okan Universitesi Tip Fakultesi View all articles by this author İbrahim AKALIN Hacettepe Universitesi Saglik Bilimleri Fakultesi View all articles by this author Oğuzhan BABACAN Dokuz Eylul Universitesi View all articles by this author İlknur SUNAR Hacettepe Universitesi Biyoloji Bolumu View all articles by this author Ayşe Sena DEMİRCİOĞLU Kocaeli Universitesi Tip Fakultesi View all articles by this author Betul Tavil Dokuz Eylul Universitesi View all articles by this author Metrics & Citations Metrics Article Usage 254 views 113 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Fatih DEMİRCİOĞLU, Zekai Avci, İbrahim AKALIN, et al. SEVERE/REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA IN A CHILD SUCCESSFULLY TREATED WITH BORTEZOMIB. Authorea . 06 February 2025. DOI: https://doi.org/10.22541/au.173883445.53583025/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.173883445.53583025/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9ff5223c28458e2e',t:'MTc3OTM4Mjc4OA=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.